CMS’ plan to lower drug spending in Medicare Advantage
From the article:
Some viewed the step as a bit of a letdown, since HHS Secretary Alex Azar has been touting more sweeping changes to drug prices in Medicare Part B, like letting the private sector insurance plans negotiate the costs of the drugs in fee-for-service Medicare plans, which serve about two-thirds of Medicare beneficiaries.
“The rhetoric surrounding the proposal is out of step with what the administration is actually doing, as has been true with many of this administration’s drug pricing actions,” said Rachel Sachs, of Washington University in St. Louis.
Read the full article.health care costs health law policy medicaremedicaid pharmaceuticals rachel sachs regulation